$10 Billion Deal, page-13067

Well written and researched @$$$$$$$$. Sorry, reply function is not working - again.

I recall that several of us commented at the time of the last CR that we thought that they would have been better off targeting HIV trials alone as a more effective use of funds rather than attempting the COVID trials (which was not looking too crash hot at the time) at the same time.

May have avoided any need for the next CR and probably quickened the pace of getting HIV results out.

We all remember the HepC "cure" and scratch our heads wondering why that opportunity was not taken into commercialisation.Very frustrating company.

The changing of priorities is illogical for a small company and somewhat of a red flag.Poor use of financial resources, changing priorities and the seemingly inability to nail down any commercial deals are flaws with BIT.